iBio (NYSE AMERICAN:IBIO) will use its FastPharming System to produce Belgium-based atbtherapeutics’ bioengineered antibody-toxin fusion proteins.
The fusion proteins, called atbodies, are being designed for the treatment of cancers. iBio will develop a manufacturing process and assays for select atbodies in this first statement of work under the parties’ master services agreement.
“We are pleased to be chosen as the process development and manufacturing partner for atbtherapeutics, whose platform technology offers a unique approach for hard-to-treat hematological malignancies and solid tumors,” Tom Isett, iBio’s chairman and CEO, said in a statement.
“We are looking forward to helping atbtherapeutics rapidly build a scalable manufacturing process so that its atbody drug candidates may quickly reach the clinic and begin to realize their potential in oncology,” he added.
Bertrand Magy, atbtherapeutics’ CEO, commented: “We are thrilled to be working with iBio, a high-quality, customer focused CDMO whose proven expertise should be highly valuable as we prepare for our first safety trials. With iBio’s support, we believe we will be able to rapidly progress toward the clinic with our lead product candidates for the treatment of cancer.”
